| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NCPONC0610 |
| P8608 | Fatcat ID | release_rdg4abo6hrcsxachsmzccpr33i |
| P698 | PubMed publication ID | 17019434 |
| P50 | author | Matthias Drosten | Q52354858 |
| P2093 | author name string | Brigitte M Pützer | |
| P2860 | cites work | MEN2A-RET-induced cellular transformation by activation of STAT3 | Q24291643 |
| Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B | Q24309625 | ||
| The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma | Q24310718 | ||
| GFRalpha1 is an essential receptor component for GDNF in the developing nervous system and kidney | Q24649094 | ||
| The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells | Q24676241 | ||
| Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase | Q24803451 | ||
| The GDNF family ligands and receptors - implications for neural development | Q28144957 | ||
| The GDNF family: signalling, biological functions and therapeutic value | Q28216478 | ||
| RET tyrosine kinase signaling in development and cancer | Q28258597 | ||
| Renal agenesis and the absence of enteric neurons in mice lacking GDNF | Q28594756 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret | Q29620364 | ||
| The specificities of protein kinase inhibitors: an update | Q30014834 | ||
| A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns] | Q31942209 | ||
| Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation | Q32125635 | ||
| A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma | Q55670928 | ||
| The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck | Q57584934 | ||
| Thyroid cancer | Q73412063 | ||
| Surgical treatment of medullary thyroid carcinoma | Q73412849 | ||
| Medullary thyroid carcinoma | Q80541075 | ||
| Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. | Q33208369 | ||
| Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection | Q33226300 | ||
| Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform | Q34097428 | ||
| Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). | Q34188803 | ||
| Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. | Q34334980 | ||
| The GDNF/RET signaling pathway and human diseases | Q34360698 | ||
| The RET receptor: function in development and dysfunction in congenital malformation | Q34390695 | ||
| Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes | Q34395743 | ||
| Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. | Q34492647 | ||
| BAY 43-9006 inhibition of oncogenic RET mutants | Q34565246 | ||
| Beyond Herceptin and Gleevec | Q35206946 | ||
| RAS and RHO GTPases in G1-phase cell-cycle regulation | Q35762468 | ||
| The RET proto-oncogene: a potential target for molecular cancer therapy. | Q35830683 | ||
| The development of imatinib as a therapeutic agent for chronic myeloid leukemia | Q35993288 | ||
| ZD6474--clinical experience to date | Q36146882 | ||
| Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration | Q36192787 | ||
| Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations | Q36550021 | ||
| A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia | Q37493754 | ||
| Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching | Q38337406 | ||
| Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism | Q39574836 | ||
| Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer | Q40355630 | ||
| Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis | Q40506925 | ||
| Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. | Q40524527 | ||
| Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors | Q40547936 | ||
| The soluble ectodomain of RetC634Y inhibits both the wild-type and the constitutively active Ret. | Q40664853 | ||
| Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors | Q40682401 | ||
| Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival | Q40768044 | ||
| Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor | Q40852922 | ||
| Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. | Q40854118 | ||
| The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis | Q40920116 | ||
| Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line | Q41367813 | ||
| Current approaches and perspectives in the therapy of medullary thyroid carcinoma | Q42503835 | ||
| Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. | Q42825417 | ||
| C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. | Q43700518 | ||
| Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases | Q44189751 | ||
| A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. | Q44255186 | ||
| Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. | Q44517288 | ||
| Evolving strategies for targeted cancer therapy--past, present, and future | Q44968981 | ||
| Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma | Q44968984 | ||
| Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase | Q45867635 | ||
| ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. | Q46469067 | ||
| Receptor tyrosine kinases as targets for anticancer therapeutics. | Q46608384 | ||
| 17-AAG: mechanisms of antitumour activity | Q46819745 | ||
| P433 | issue | 10 | |
| P921 | main subject | thyroid carcinoma | Q18556131 |
| P304 | page(s) | 564-574 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Nature Clinical Practice Oncology | Q15752073 |
| P1476 | title | Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy | |
| P478 | volume | 3 |
| Q94367553 | Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation |
| Q41251561 | Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma |
| Q45866246 | Evaluation of systemic targeting of RET oncogene-based MTC with tumor-selective peptide-tagged Ad vectors in clinical mouse models |
| Q38719786 | GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. |
| Q90669004 | Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing |
| Q40036483 | Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates |
| Q38035208 | Hearing impairments caused by genetic and environmental factors |
| Q37311366 | High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. |
| Q39450576 | High-resolution analysis of alterations in medullary thyroid carcinoma genomes |
| Q37531200 | Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer |
| Q37921599 | Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. |
| Q35038893 | Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies |
| Q39015324 | MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET. |
| Q38719449 | MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit |
| Q34726233 | New therapeutic approaches to treat medullary thyroid carcinoma |
| Q37038500 | Novel targets in non-small cell lung cancer: ROS1 and RET fusions |
| Q40922523 | Personalization of targeted therapy in advanced thyroid cancer |
| Q47964521 | Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. |
| Q38425184 | Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements. |
| Q37979656 | RET TKI: potential role in thyroid cancers. |
| Q37134454 | RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer |
| Q36960954 | RET signaling in endocrine tumors: delving deeper into molecular mechanisms. |
| Q38546474 | Selective use of vandetanib in the treatment of thyroid cancer |
| Q38118647 | Sorafenib and thyroid cancer |
| Q38960074 | The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. |
| Q38614485 | Thyroid C-Cell Biology and Oncogenic Transformation. |
| Q30428632 | XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. |
| Q33565577 | c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines |
| Q30477530 | c-Ret-mediated hearing loss in mice with Hirschsprung disease |
| Q37980452 | c-Ret-mediated hearing losses |
| Q64986657 | miR-149-5p inhibits cell proliferation and invasion through targeting GIT1 in medullary thyroid carcinoma. |
| Q93185081 | miRNA-15a regulates the proliferation and apoptosis of papillary thyroid carcinoma via regulating AKT pathway |
Search more.